N/A N=48 Cohort Isolation and Cross-infection in Bronchiolitis
Bronchiolitis
Primary: Duration of Hospital Stay — 3.9; 2.1 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Respiratory Syncytial Virus - RSV Protocol
Bone Marrow Transplant Infection · Infection in Marrow Transplant Recipients · Respiratory Syncytial Virus Infections
Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants
N/A N=152 Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
Bronchiolitis · Bronchiolitis, Viral · RSV Infection
Primary: The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling — 124; 60; 0; 0 Sampling visits
N/A N=343 Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)
Respiratory Syncytial Virus Bronchiolitis
Primary: Percentage of Participants With Asthma at 6 Years of Age: Overall and by Prognostic Factor — 6.1; 11.2; 3.1; 9.6 percentage of participants
N/A N=58 The Development of a Human Model of Respiratory Syncytial Virus Infection
Respiratory Syncytial Virus Infections · Respiratory Viral Infections
Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants
N/A N=2,401 A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age
Respiratory Syncytial Virus
Primary: Incidence Rates of First Episode of Respiratory Syncytial Virus (RSV) Respiratory Tract Infection (RTI) [Period 1] — 7.93 Cases per 100 person-years
N/A N=59 Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Bronchiolitis · Respiratory Syncytial Virus Infections
Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020
N/A N=161 Intermittent Versus Continuous Pulse Oximetry Monitoring of Infants Admitted for Bronchiolitis
Bronchiolitis · Hypoxia
Primary: Length of Stay in the Hospital — 38.7; 39.5 hours — p=<0.05
Phase 2 N=40 Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis
RSV Bronchiolitis
Primary: IL-8 Concentrations — 12,795; 14,676 Pg/ml — p=0.6
Phase 2 N=22 A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease
Respiratory Syncytial Viruses
Primary: Respiratory Syncytial Virus (RSV) Viral Load-time Curve From Immediately Prior to First Dose of JNJ-53718678 Through Day 5 (AUC [Day 1-5]) — 26.13; 25.10 log10…
N/A N=82 Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection
Respiratory Syncytial Virus Infection
Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants
Phase 4 N=50 Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
Hematological Malignancies
Primary: Occurrences of Pneumonia — 4; 3 Participants
Phase 3 N=200 Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II
Respiratory Syncytial Virus, Bronchiolitis
Primary: Number of Participants Who Experienced the Occurrence of a Third Episode of Post-RSV Wheezing (Recurrent Wheeze) — 45; 33 Participants — p=0.08
Phase 1 N=45 Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children
RSV Infection
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade - (RSV-seropositive Participants) — 8; 5; 0; 0 Participants
Phase 4 N=64 Nebulized 3% Hypertonic Saline Solution Treatment of Bronchiolitis in Infants
Bronchiolitis · Wheezing
Primary: Score Respiratory Distress — 8; 8; 6; 8 units on a scale
Phase 3 N=100 Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
Respiratory Syncytial Virus Infection · Premature Birth · Bronchopulmonary Dysplasia
Primary: Frequency of Adverse Events — 41 participants
Phase 1 N=60 Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children
RSV Infection
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade (RSV-seropositive Participants) — 10; 9; 4; 0 Participants
N/A N=227 A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis
Bronchiolitis
Primary: Length of Stay in the Study-LOS--Intention to Treat Analysis — 2.1; 2.1 Days — p=0.73
N/A N=304 The Bronchiolitis Follow-up Intervention Trial
Bronchiolitis
Primary: Parental Anxiety — 4.2; 3.9 points on a scale
Phase 2 N=21 RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
Upper Respiratory Tract Infection · Lower Respiratory Tract Infection
Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change
Phase 2 N=48 Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children
Respiratory Syncytial Virus
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0 participants
N/A N=91 Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children
Respiratory Syncytial Virus Infection
Primary: Nasal Interferon (IFN)-a2 — 10; 26 pg/ml — p=0.04
Phase 4 N=62 Hypertonic Saline for Acute Bronchiolitis
Bronchiolitis, Viral · Saline Solution, Hypertonic
Primary: Respiratory Assessment Change Score (RACS) — -1.5; -4 units on a scale — p=0.01
N/A N=228 Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters
Bronchiolitis
Primary: Number of Caregiver-reported Symptom-free Days (SFDs) — 118.01; 112.60 Days — p=0.537
Phase 1 N=33 Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 16; 10; 0; 0 Participants
Phase 2 N=180 Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Primary: Time for Viral Load to Drop Below Assay Quantification Limit (BQL) (Plaque Assay Analysis) — 46.1; 14.2; 5.1; 5.1 hours — p=<0.001
N/A N=103 The Effectiveness of AAD and IPV to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis.
Bronchiolitis
Primary: Length of Hospital Stay — 3.5; 3.6; 4.5 days
Phase 1 N=32 Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 17; 9; 3; 1 Participants
Phase 2 N=201 Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
Respiratory Syncytial Virus Infections
Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) During a 7-day Follow-up Period After the First Vaccination (Administered at Day 1) — 5; 6; 0; 22…
Phase 1 N=24 A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV
Respiratory Syncytial Virus Infections
Primary: Number of Subjects With Required Adverse Events Grade II, III, and IV, Laboratory Adverse Events Grade II, III, and IV, and Severe Considered Adverse Events Related to…